Upstream Bio Inc

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chronic Rhinosinusitis market is expected to reach $3.5 billion by 2027.

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.

Upstream Bio Announces Addition to Russell 2000® Index

ArriVent Biopharma Inc

CG oncology Inc

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the closing of its upsized initial public offering of 17,250,000 shares of its common stock at a public offering price of $17.00 per share, which includes 2,250,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock.

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio , which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States.

Upstream Bio raises $255 mln in US IPO

WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the pricing of its upsized initial public offering of 15,000,000 shares of its common stock at a public offering price of $17.00 per share.

Upstream Bio Announces Pricing of Upsized Initial Public Offering

News for Upstream Bio Inc Stock (UPB)